作者: Mark L. Janzen , Viktor Y. Dombrovskiy , Edgar Luis Galiñanes , Todd R. Vogel
关键词: In patient 、 Clopidogrel 、 Medicare population 、 Amputation 、 Lower extremity revascularization 、 Surgery 、 Medicine 、 Claudication 、 Overall survival 、 Current Procedural Terminology
摘要: Objective: To evaluate freedom from amputation in patients identified utilizing clopidogrel following their lower extremity endovascular revascularization (LER). Methods: Patients, 65 years of age and older, undergoing LER were Medicare Provider Analysis Review Carrier files International Classification Diseases diagnosis Current Procedural Terminology codes. Postprocedural use was using the National Drug Code directory. Outcomes evaluated. Results: A total 14 353 identified: 5697 (39.7%) with claudication, 1467 (10.2%) rest pain, 7189 (50.1%) ulceration/tissue loss. In all, 5416 (37.7%) after LER. Overall, initiated on had rates at 30 days (10.34% vs 14.09%; P < .0001), 90 (14.05% 18.71%; 1 year (19.68% 24.06%;P .0001). Conclusion: Utilization associated amputation, yet only 38% population as clopidogrel. Patients ulceration tissue loss benefited most significantly greater overall survival.